Clinical Trials Logo
  1. Home
  2. Intermittent Claudication
  3. NCT03446027

Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients With Intermittent Claudication Compared to Best Available Treatment? — NESIC  

Intermittent Claudication Clinical Trial

Official title:
A Multicenter Randomised Controlled Study: Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients With Intermittent Claudication (NESIC) Compared to Best Available Treatment?

Clinical Trial Summary

Intermittent claudication (IC) is caused by a blockage in the artery of the leg, causing muscle pain. Although some evidence of the efficacy of neuromuscular electrical stimulation (NMES) in the management of patients with IC exists, further high quality research is required. This proposed study is vital to identify the contribution of clinical change using NMES, compared to the current gold standard recommended practice of supervised exercise therapy (SET) and, actual standard of care offered in the majority of the UK and Ireland, including best medical therapy (BMT). The device is expected to increase the walking distance in patients with intermittent claudication (IC), and therefore have a benefit on the same when provided in addition to supervised exercise programmes. It is also expected to cause a reduction in pain symptoms and reduced likelihood of major intervention in late stage peripheral arterial disease (PAD). The principal research objective is to assess the clinical efficacy of a neuromuscular electrical stimulation (NMES) device as an adjunct to the local standard care that is available at the study randomisation sites, in order to improve walking distance in patients with intermittent claudication (IC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03446027
Study type Interventional
Source Imperial College London
Contact
Status Completed
Phase N/A
Start date February 16, 2018
Completion date September 30, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05400395 - Clinical Trial for GNX80 in Intermittent Claudication Phase 4
Active, not recruiting NCT02341716 - Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication N/A
Completed NCT02041169 - Lower Extremity Peripheral Arterial Disease and Exercise Ischemia N/A
Completed NCT00822172 - Evaluation of Cilostazol in Combination With L-Carnitine Phase 4
Recruiting NCT00538408 - Whole Body Magnetic Resonance Angiography in Ischemic Patients N/A
Completed NCT00618670 - Home-based vs. Supervised Exercise for People With Claudication N/A
Completed NCT00388128 - Caffeine and Intermittent Claudication Phase 3
Recruiting NCT00146666 - Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD) Phase 2
Completed NCT00134277 - Trial Comparing Different Medical Devices for Infragenual Dilatation N/A
Completed NCT01256775 - Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD) Phase 2
Completed NCT00029991 - Extract of Ginkgo Biloba (EGB 761) and Vascular Function Phase 1/Phase 2
Recruiting NCT06299956 - Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark N/A
Not yet recruiting NCT05335161 - A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease Phase 1
Completed NCT04390282 - Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication N/A
Completed NCT03271710 - Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System N/A
Completed NCT02380794 - Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule Phase 2
Active, not recruiting NCT02276937 - Randomized Phase IIb Trial of DVC1-0101 Phase 2
Completed NCT02097082 - Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System N/A
Recruiting NCT00539266 - Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia Phase 2/Phase 3
Completed NCT00071266 - The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC Phase 3